14 December 2016 - Stelara offers a new approach to treating Crohn's disease in Canada, which has one of the highest rates of this inflammatory bowel disease worldwide.

Janssen announced today that Health Canada has issued a Notice of Compliance for Stelara (ustekinumab) indicated for the treatment of adult patients with moderately to severely active Crohn's disease, who have had an inadequate response, loss of response to, or were intolerant to either immunomodulators or one or more tumour necrosis factor-alpha antagonists, or have had an inadequate response, intolerance or demonstrated dependence on corticosteroids.

Stelara is the first and only biologic therapy for Crohn's disease targeting interleukin 12 and interleukin 23, which play a key role in inflammatory and immune responses.

Read Janssen press release